Sagent Pharmaceuticals, a leading provider of pharmaceuticals to the US market, has announced its entry into the ophthalmic market with the launch of Travoprost Ophthalmic Solution, USP 0.004%.

Travoprost is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension and represents a USD 61 million market in the 12 months ended July 2025.

Sagent plans to expand its ophthalmic product portfolio with more products in the coming year. With these product launches, Sagent aims to address the growing demand for high-quality, accessible eye care treatments throughout the US. According to IQVIA, the combined total addressable ophthalmic market is expected to exceed USD 8.6 billion.

"Expanding into the ophthalmic space marks a significant step in broadening our portfolio and reinforcing our trajectory of sustainable growth,” said Dr. Vishy Chebrol, CEO of Sagent.

"We remain guided by our mission to improve patient outcomes, while leveraging our proven strengths in quality and reliability to ensure dependable access and long-term value,” he added.

Sagent’s portfolio of more than 100 products spans a wide range of therapeutic areas, with flexible formulations and packaging options including vials, syringes, premix bags, and ophthalmic solutions.